頭頚部悪性腫瘍患者の免疫能に関する臨床的研究--古典経路と第2経路における血清補体価および補体成分を中心として

スポンサーリンク

概要

• 論文の詳細を見る

• In 274 patients with cancer of the head and neck, the serum complement levels (CH50, AP50) and complement proteins (C1q, C4, C3c, C3PA, C5 and C9) in the classical and alternative pathways were determined.The assay procedure used was Mayer's 50% hemolysis method for CH50, and Takada's method utilizing rabbit erythrocytes for AP50. Complement proteins were determined using the partigen plate, with QS serum for C1q, C5 and C9, protein-standard plasma for C4, C3c and C3PA.The results show that the CH50 value was higher in patients with cancer of the head and neck than in healthy persons, and more markedly elevated in patients with advanced cancer than in those with early cancer.CH50 was related to the clinical course in such a manner that it was elevated in a cancer-bearing state, i. e., in untreated patients and those with recurrence or metastasis, and normal or nearly normal in patients in a state of remission or 5-year cure. It tended to be elevated after irradiation or operation, while being variable in patients with terminal cancer.The AP50 value was higher in patients with cancer of the head and neck than in healthy persons, and varied in correspondence to the clinical course as CH50 was. It was slightly lowered but variable in patients with terminal cancer.The complement proteins C4, C3c, C3PA, C5 and C9 were significantly higher in patients with cancer of the head and neck than in healthy persons.The above findings suggest that, in cancer-bearing hosts with reduced cellular immunity, humoral immunity mainly residing in the complement system is called upon to compensate for the fall in cellular immunity to maintain the immune system of the host with the resulting "complement response". The present data further suggest that not only the classical but also the alternative pathway was involved in the complement response.

• 耳鼻咽喉科臨床学会の論文

著者

• 小津 雷助

  慶応義塾大学医学部耳鼻咽喉科学教室

関連論文

• 当教室における重複悪性腫瘍症例及び本邦報告例の統計的観察
• 頭頸部悪性腫瘍における抗EBウィルス抗体価
• 上咽頭癌における臨床経過と抗EBウイルス抗体価との関連について
• 頭頚部悪性腫瘍に対するOK-432の効果について
• 頭頚部悪性腫瘍に対するNK-631(Pepleomycin)の臨床効果
• 上顎肉腫治療の現況 自験例の検討および文献的考察
• 副鼻腔真菌症に関する臨床的観察
• 頭頚部悪性腫瘍に対する油性ブレオマイシン局注療法
• Rhinocerebral mucormycosisの1剖検例及び本疾患に関する統計的観察
• 頭頚部悪性腫瘍における免疫学的検討--「ツ反応と補体による6期分類」を中心として
• 頭頚部悪性腫瘍患者の免疫能に関する臨床的研究--古典経路と第2経路における血清補体価および補体成分を中心として

もっと見る 閉じる

スポンサーリンク